Imagine having a personalized weather forecast for your gut health that warns you before a storm hits. Instead of waiting for a disease to cause pain, this system looks at your genes, diet, and lifestyle to spot early warning signs. It's like a smart alarm system that tells you exactly what to change in your diet to keep your intestines healthy.
IBD is often diagnosed too late, causing high healthcare costs and poor patient outcomes. There is a lack of personalized tools to detect the transition from health to disease before symptoms become severe.
Software for analyzing genetic and inflammation markers, mobile apps for nutrition and activity tracking, and a co-culture system using human intestinal organoids.
If you are a health-tech app developer dealing with low user retention in chronic care — this project developed sensors and mobile apps that dynamically monitor nutrition and physical activity. This allows users to track their health status in real-time and engage in proactive self-care.
If you are a personalized nutrition provider dealing with a lack of clinical evidence for diet plans — this project developed a proof-of-concept trial on nutrient elimination diets. This provides a blueprint for using microbiome-derived metabolites to restore gut barrier function.
If you are a diagnostics lab dealing with late-stage IBD detection — this project developed a method to combine genetic data with inflammation markers. This identifies actionable biomarkers that predict the transition from health to disease.
Based on available project data, specific pricing or cost per unit is not provided; however, the project aims to reduce societal costs by as much as 10%.
The project involves 13 partners across 10 countries, including 2 SMEs, suggesting a multi-regional approach to scaling the software and sensor tools.
Based on available project data, specific licensing terms are not mentioned, but the project focuses on creating tools and software for biomarker analysis.
It integrates via eHealth tools, mobile apps, and sensors designed for both patients and healthcare professionals to monitor health status dynamically.
The project is active from 2023-01-01 to 2026-12-31.
The consortium is heavily research-driven with 9 universities and 2 other non-profit/research entities, but maintains a 15% industry ratio through 2 SMEs. This balance suggests the project is focused on high-science validation (omics and organoids) while ensuring the output is translated into usable eHealth tools and sensors.
Contact Universitätsklinikum Schleswig-Holstein in Germany
Contact us to connect with the miGut-Health consortium for licensing biomarker tools.
